Intelect Medical Inc.

Intelect Medical is developing targeted neuromodulation technologies and therapies to improve patient outcomes. Intelect's neuromodulation technologies include: • GUIDE DBS, a deep brain stimulation programming system, conceived of by Cameron McIntyre, Ph.D., Chris Butson, Ph.D. and their colleagues at Cleveland Clinic that will provide neurologists with an intuitive method of visualizing DBS electrodes, anatomical structures, and proprietary "target volumes", to maximize therapeutic efficacy of DBS while minimizing commonly observed side effects. • Accupoint DBS leads, the next generation of deep brain stimulation leads that allow for "targeting" stimulation fields towards desired brain regions and away from potential side effect causing regions. Intelect's neuromodulation therapies in pre-clinical and clinical research stage include DBS for recovery of chronic stroke patients, based on the work of Andre Machado, M.D. of Cleveland Clinic, and DBS for recovery following TBI, based on the work of Nicholas Schiff, M.D., of Weill-Cornell Medical College.

• Employees 1
• Founded 2005
• Annual Revenue $6386000
• Total Funding $11000000